Drugs / SHC014748M
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04006860 | Jul → Dec 2019 | — | Nanjing Sanhome Pharmaceutical, Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT03588598 | Sep 2018 → Jul 2019 | chronic lymphocytic leukemia/small lymphocytic lymphoma | Nanjing Sanhome Pharmaceutical, Co., Ltd. | Unknown | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04470141 | Aug 2020 → May 2021 | peripheral T-cell lymphoma, not otherwise specified | Nanjing Sanhome Pharmaceutical, Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT04431089 | May 2020 → Apr 2021 | follicular lymphoma, marginal zone lymphoma | Nanjing Sanhome Pharmaceutical, Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SHC014748M | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03588598 ↗ |
| Action | Inhibit | “a selective PI3Kδ inhibitor” NCT03588598 ↗ |
| Route | Oral | “an oral inhibitor of PI3K delta” NCT03588598 ↗ |